Monoclonal antibodies (mAbs) are used extensively in the diagnostics industry, where their superior selectivity and binding greatly increases the robustness of such tests. This webinar describes an approach for efficient scale-up of a bench-scale mAb process.
Topics to be covered include:
This in-depth webinar will be valuable for all of those involved in bringing diagnostic assays to market including:
Senior Manager, Downstream Technologies, BioContinuum™ Platform
Paul holds a B.S. in biochemistry from Imperial College London and has an M.S. and Ph.D. in biochemical engineering from University College London. Paul has worked in the pharmaceutical industry for 20 years and has held a number of roles in this capacity, including managing bioprocesses for early phase clinical material, CMC regulatory affairs consultancy, and downstream bioprocessing technology consultancy. Currently, Paul is a senior manager responsible for the DSP strategy for the BioContinuum™ next-generation processing platform.
To continue reading please sign in or create an account.Don't Have An Account?